Search

Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation proudly announce the distinguished MSK nurses who were honored with the 2025 Robbins Family Award for Nursing Excellence.

… Friday, May 9, 2025 Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation proudly announce the distinguished MSK nurses who were honored with the 2025 Robbins Family Award for Nursing Excellence. The awards coincide with National Nurses Week and are supported by the Robbins Family

Semanti Mukherjee successfully defended her thesis in September 2011. Her project focused on the genetic variants that contribute to the predisposition for and etiology of myeloproliferative neoplasms.

… Tuesday, November 1, 2011 About Semanti Mukherjee’s Dissertation Research Semanti worked on her thesis project under the guidance of  Robert Klein in the Cancer Biology and Genetics Program. Her project focused on the genetic variants that contribute to predisposition for and etiology of myeloproliferative

An epigenetic mechanism may make small cell lung cancer vulnerable to a new kind of attack.

… Monday, February 13, 2017 Summary Small cell lung cancer (SCLC) is notoriously difficult to treat because it quickly acquires resistance to chemotherapy. Scientists at Memorial Sloan Kettering have uncovered a molecular mechanism by which SCLC cells develop resistance, opening the door to new treatments

Learn how to manage menopause symptoms if you have breast cancer

… Friday, October 28, 2016 Summary The menopause symptoms that can sometimes happen as a result of breast cancer treatment are an unwelcome side effect. Memorial Sloan Kettering medical oncologist Shari Goldfarb shares her recommendations for how women can find relief. Highlights Women with breast cancer

Having two mutated copies of the TP53 gene — as opposed to a single mutated copy — is associated with worse outcomes in a blood cancer called myelodysplastic syndrome, according to a new study led by researchers at Memorial Sloan Kettering.

… Monday, August 3, 2020 Summary A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia. Considered the “guardian of the genome,” TP53 is the most commonly

An uptick in colorectal cancer in people under the age of 50 is an alarming trend that led Memorial Sloan Kettering to develop the first of its kind Center for Young Onset Colorectal Cancer in 2018. Read more.

… Monday, August 31, 2020 VIDEO | 01:05 Learn More about MSK's Center for Young Onset Colorectal Cancer Gastroenterologist Robin Mendelsohn explains how young people with colorectal cancer are treated at MSK. She also discusses ongoing research into the causes of young onset colorectal cancer. Video Details

LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food and Drug Administration expanded access program were presented by David Hyman, MD, the Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK), at the American Association for Cancer Research (AACR) Annual Meeting 2019. This research is featured in the meeting’s press program, and findings are being presented in the “Next Generation of Clinical Trials in Molecularly Driven Therapy” minisymposium.

… Monday, April 1, 2019 LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food

Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused February 9 issue of Cell, the article — “Implementing Genome-Driven Oncology” — presents a critically self-reflective but solutions-focused perspective on this approach to cancer treatment.

… Thursday, February 9, 2017 Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

… Wednesday, August 25, 2010 A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma . Investigators at Memorial Sloan Kettering Cancer Center and colleagues

… Monday, November 9, 2020 Miriam Lorena Murray estaba en la mejor condición física de su vida cuando recibió una desgarradora noticia: su médico le diagnosticó, cáncer de mama. “Estaba en un estado dos ya pasando a un estado tres y sin ningún síntoma, viéndome espectacular”, contó Miriam Lorena de 50